Optimising Protection for Pregnant Women and Infants With Maternal Vaccination

Active, not recruitingOBSERVATIONAL
Enrollment

73

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

September 29, 2023

Study Completion Date

March 1, 2024

Conditions
Obesity
Interventions
BIOLOGICAL

Quadrivalent Influenza Vaccine

Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.

BIOLOGICAL

DTP Vaccine (Multiple Actives)

Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.

Trial Locations (1)

5006

Women's and Children's Hospital, North Adelaide

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Women's and Children's Hospital, Australia

OTHER_GOV